The Most-Favored-Nation (MFN) pricing model aims to align the cost of brand-name drugs in the U.S. with the lowest prices offered in other wealthy nations.
Universities could risk losing their access to federal funding if they are found to be ‘discriminating against their students,’ the Department of Justice said.